ArticleOncotarget2024
Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer.
S H Tolmeijer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it